[Therapeutic efficacy and prognostic factors in diffuse astrocytomas].
Diffuse astrocytomas are slowly growing tumors with a relatively long overall survival. Considerable controversy exists as to the best therapeutic management for patients with such tumors. In the present study, we retrospectively analyzed a series of 64 patients with WHO grade II astrocytomas of the cerebral hemispheres. Gross total resection and interferon-beta therapy were significantly associated with both longer progression free survival (PFS) and overall survival (OS). Immediate postoperative radiation therapy did not prolong either the PFS or OS. The presence of promoter hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene was an independent predictor of a shorter PFS. Our data suggest that radical surgery plus interferon-beta therapy may offer the best chance for long survival. Since the presence of MGMT methylation is a probable indication of an increased sensitivity to alkylating chemotherapeutic agents, determining the methylation status of MGMT could provide a potential basis for logical therapeutic intervention in identifying a subgroup of patients who could be candidates for early chemotherapy.
Watanabe
Takao
T
Department of Neurological Surgery, Nihon University School of Medicine, Japan.
Komine
Chiaki
C
Yokoyama
Takakazu
T
Yoshino
Atsuo
A
Katayama
Yoichi
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000235:genetics / Q000628:therapy*; D001932:Brain Neoplasms / Q000235:genetics / Q000628:therapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008745:Methylation; D008875:Middle Aged; D019635:Neurosurgical Procedures; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics; D011379:Prognosis; D012189:Retrospective Studies
D016899:Interferon-beta; D019853:O(6)-Methylguanine-DNA Methyltransferase